Hualan Biological Engineering Inc. (SHE:002007)
13.34
+0.32 (2.46%)
Sep 30, 2026, 3:04 PM CST
SHE:002007 Revenue
Hualan Biological Engineering had revenue of 804.53M CNY in the quarter ending June 30, 2026, a decrease of -13.55%. This brings the company's revenue in the last twelve months to 4.36B, down -3.56% year-over-year. In the year 2025, Hualan Biological Engineering had annual revenue of 4.60B with 4.93% growth.
Revenue (ttm)
4.36B
Revenue Growth
-3.56%
P/S Ratio
5.58
Revenue / Employee
1.06M
Employees
4,117
Market Cap
24.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.60B | 215.82M | 4.93% |
| Dec 31, 2024 | 4.38B | -962.68M | -18.02% |
| Dec 31, 2023 | 5.34B | 824.89M | 18.26% |
| Jan 1, 2023 | 4.52B | 80.78M | 1.82% |
| Jan 1, 2022 | 4.44B | -587.01M | -11.69% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chongqing Zhifei Biological Products | 8.05B |
| Beijing Tiantan Biological Products | 5.65B |
| Yili Chuanning Biotechnology | 4.37B |
| Xiamen Amoytop Biotech | 4.02B |
| Suzhou Zelgen Biopharmaceuticals | 1.64B |
| Sinocelltech Group | 1.25B |
| Evopoint Biosciences | 1.11B |
| Acrobiosystems | 950.35M |
Hualan Biological Engineering News
- 5 weeks ago - Hualan Biological Engineering Quarterly report: Q2 2026 - Filings
- 5 months ago - Hualan Biological Engineering Quarterly report: Q1 2026 - Filings
- 6 months ago - Hualan Biological Engineering Annual report: H2 2025 - Filings
- 11 months ago - Hualan Biological Engineering Quarterly report: Q3 2025 - Filings